BAKER BROS. ADVISORS LP Q1 2022 Filing
Filed May 16, 2022
Portfolio Value
$17.4B
Holdings
118
Report Date
Q1 2022
Filing Type
13F-HR
All Holdings (118 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | 46,912,266 | $6.8T | 38829.70% | |
| 2 | INCYIncyte Corporation | 36,153,684 | $2.9T | 16498.59% | |
| 3 | ONCBeiGene, Ltd. | 11,668,897 | $2.2T | 12645.50% | |
| 4 | ACADACADIA Pharmaceuticals Inc. | 41,910,704 | $1.0T | 5832.62% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 7,620,494 | $587.5B | 3375.99% | |
| 6 | ASNDAscendis Pharma A/S | 4,541,604 | $533.0B | 3062.63% | |
| 7 | ARGXargenx SE | 1,119,557 | $353.0B | 2028.38% | |
| 8 | BCRXBioCryst Pharmaceuticals, Inc. | 12,710,818 | $206.7B | 1187.57% | |
| 9 | MDGLMadrigal Pharmaceuticals, Inc. | 1,499,213 | $147.1B | 845.25% | |
| 10 | KODKodiak Sciences Inc. | 15,931,045 | $123.0B | 706.69% | |
| 11 | MRTXEURMirati Therapeutics, Inc. | 1,409,784 | $115.9B | 666.03% | |
| 12 | GBTUSDGlobal Blood Therapeutics, Inc. | 3,314,765 | $114.8B | 659.77% | |
| 13 | ABCLAbCellera Biologics Inc. | 10,450,180 | $101.9B | 585.45% | |
| 14 | KYMRKymera Therapeutics, Inc. | 2,384,742 | $100.9B | 579.90% | |
| 15 | HZNPHorizon Therapeutics Public Ltd Co | 898,842 | $94.6B | 543.38% | |
| 16 | TVTXTravere Therapeutics, Inc. | 3,300,009 | $85.0B | 488.64% | |
| 17 | 1K0IGM Biosciences, Inc. | 3,156,102 | $84.4B | 484.75% | |
| 18 | NVTA1EURInvitae Corporation | 9,873,488 | $78.7B | 452.16% | |
| 19 | IMCRImmunocore Holdings plc | 2,520,730 | $75.4B | 433.07% | |
| 20 | CERSCerus Corporation | 13,713,195 | $75.3B | 432.59% | |
| 21 | LEGNLegend Biotech Corporation | 2,008,999 | $73.0B | 419.50% | |
| 22 | PRLDPrelude Therapeutics Inc. | 10,123,824 | $69.9B | 401.38% | |
| 23 | AMRNAmarin Corporation plc | 21,169,805 | $69.6B | 400.20% | |
| 24 | NBIXNeurocrine Biosciences, Inc. | 676,975 | $63.5B | 364.67% | |
| 25 | MRUSMerus N.V. | 2,037,469 | $53.9B | 309.54% | |
| 26 | KRYSKrystal Biotech, Inc. | 807,735 | $53.7B | 308.83% | |
| 27 | IM8NInsmed Incorporated | 2,156,001 | $50.7B | 291.13% | |
| 28 | PACBPacific Biosciences of California, Inc. | 5,444,963 | $49.5B | 284.71% | |
| 29 | RYTMRhythm Pharmaceuticals, Inc. | 4,125,062 | $47.5B | 273.05% | |
| 30 | HRTXHeron Therapeutics, Inc. | 8,131,678 | $46.5B | 267.26% | |
| 31 | TRDAEntrada Therapeutics, Inc. | 4,704,419 | $44.2B | 253.82% | |
| 32 | TILInstil Bio, Inc. | 3,893,700 | $41.9B | 240.51% | |
| 33 | ALKSAlkermes plc | 1,500,000 | $39.5B | 226.77% | |
| 34 | INSM 0.75 06/01/28Insmed Incorporated | 40,000,000 | $38.6B | 221.88% | |
| 35 | SRPT 1.5 11/15/24Sarepta Therapeutics, Inc. | 29,174,000 | $38.4B | 220.41% | |
| 36 | 290AChinook Therapeutics, Inc. | 2,334,102 | $38.2B | 219.42% | |
| 37 | VSTMVerastem, Inc. | 26,988,898 | $38.1B | 218.66% | |
| 38 | AVTEAerovate Therapeutics, Inc. | 2,070,010 | $37.9B | 218.02% | |
| 39 | IMTXImmatics N.V. | 4,423,731 | $35.3B | 203.10% | |
| 40 | TSVT*2seventy bio, Inc. | 2,062,744 | $35.2B | 202.20% | |
| 41 | NRIXNurix Therapeutics, Inc. | 2,454,082 | $34.4B | 197.56% | |
| 42 | VERVVerve Therapeutics, Inc. | 1,416,530 | $32.3B | 185.74% | |
| 43 | RAREUltragenyx Pharmaceutical Inc. | 444,444 | $32.3B | 185.46% | |
| 44 | KNSAKiniksa Pharmaceuticals, Ltd. | 2,799,577 | $27.8B | 159.90% | |
| 45 | REPLReplimune Group, Inc. | 1,611,703 | $27.4B | 157.25% | |
| 46 | AXSMAxsome Therapeutics, Inc. | 610,970 | $25.3B | 145.30% | |
| 47 | —DBV Technologies S.A. | 14,614,264 | $23.2B | 133.52% | |
| 48 | DSGNDesign Therapeutics, Inc. | 1,436,636 | $23.2B | 133.32% | |
| 49 | CCXIEURChemoCentryx, Inc. | 916,862 | $23.0B | 132.08% | |
| 50 | XENEXenon Pharmaceuticals Inc. | 751,639 | $23.0B | 132.03% | |
| 51 | —Affimed N.V. | 5,153,169 | $22.5B | 129.39% | |
| 52 | ADAPYAdaptimmune Therapeutics plc | 9,830,877 | $20.3B | 116.37% | |
| 53 | —Forma Therapeutics Holdings, Inc. | 2,024,876 | $18.8B | 108.20% | |
| 54 | OTICEUROtonomy, Inc. | 7,844,692 | $18.8B | 108.18% | |
| 55 | OPTEYOpthea Limited | 2,696,191 | $18.5B | 106.21% | |
| 56 | CRNXCrinetics Pharmaceuticals, Inc. | 827,480 | $18.2B | 104.36% | |
| 57 | 1T7Tricida, Inc. | 1,731,714 | $14.2B | 81.79% | |
| 58 | RLMDRelmada Therapeutics, Inc. | 495,113 | $13.4B | 76.78% | |
| 59 | FLGTFulgent Genetics, Inc. | 201,444 | $12.6B | 72.24% | |
| 60 | —bluebird bio, Inc. | 2,499,715 | $12.1B | 69.66% | |
| 61 | —DICE Therapeutics, Inc. | 588,235 | $11.3B | 64.66% | |
| 62 | BCELAtreca, Inc. | 3,532,760 | $11.2B | 64.35% | |
| 63 | —Zymeworks Inc. | 1,708,472 | $11.2B | 64.30% | |
| 64 | —Athira Pharma, Inc. | 806,367 | $10.9B | 62.55% | |
| 65 | —Talis Biomedical Corporation | 7,624,835 | $10.8B | 61.78% | |
| 66 | ANABAnaptysBio, Inc. | 427,179 | $10.6B | 60.72% | |
| 67 | CNTACentessa Pharmaceuticals plc | 1,127,273 | $10.1B | 58.10% | |
| 68 | SRPTSarepta Therapeutics, Inc. | 123,456 | $9.6B | 55.41% | |
| 69 | KRTXKaruna Therapeutics, Inc. | 69,966 | $8.9B | 50.97% | |
| 70 | —Invitae Corporation | 10,300,000 | $8.4B | 48.15% | |
| 71 | AGLEUSDAeglea BioTherapeutics, Inc. | 3,410,106 | $7.8B | 45.07% | |
| 72 | VERAVera Therapeutics, Inc. | 333,333 | $7.8B | 44.99% | |
| 73 | 698Achilles Therapeutics plc | 2,591,366 | $7.6B | 43.78% | |
| 74 | SRZNSurrozen, Inc. | 2,500,000 | $7.5B | 43.24% | |
| 75 | RETAEURReata Pharmaceuticals, Inc. | 223,976 | $7.3B | 42.16% | |
| 76 | —Neoleukin Therapeutics, Inc. | 3,821,740 | $7.2B | 41.28% | |
| 77 | FGENEURFibroGen, Inc. | 581,750 | $7.0B | 40.18% | |
| 78 | BMEABiomea Fusion, Inc. | 1,551,445 | $6.9B | 39.76% | |
| 79 | CBAYUSDCymaBay Therapeutics, Inc. | 2,170,464 | $6.8B | 38.79% | |
| 80 | ALTAltimmune, Inc. | 1,072,038 | $6.5B | 37.52% | |
| 81 | HRMYHarmony Biosciences Holdings, Inc. | 123,600 | $6.0B | 34.55% | |
| 82 | TNGXTango Therapeutics, Inc. | 750,000 | $5.7B | 32.67% | |
| 83 | RVMDRevolution Medicines, Inc. | 222,222 | $5.7B | 32.57% | |
| 84 | HOOKGBPHOOKIPA Pharma Inc. | 2,400,481 | $5.5B | 31.45% | |
| 85 | EWTXEdgewise Therapeutics, Inc. | 500,000 | $4.8B | 27.87% | |
| 86 | 5E7Iteos Therapeutics, Inc. | 150,346 | $4.8B | 27.80% | |
| 87 | ALGSAligos Therapeutics, Inc. | 2,076,400 | $4.5B | 25.65% | |
| 88 | NGMUSDNGM Biopharmaceuticals, Inc. | 291,801 | $4.5B | 25.57% | |
| 89 | KURAKura Oncology, Inc. | 274,458 | $4.4B | 25.36% | |
| 90 | BCABBioAtla, Inc. | 825,000 | $4.1B | 23.70% | |
| 91 | ALLKGUSDAllakos Inc. | 703,050 | $4.0B | 23.02% | |
| 92 | TCRXTScan Therapeutics, Inc. | 1,425,000 | $4.0B | 22.93% | |
| 93 | MGNXMacroGenics, Inc. | 442,579 | $3.9B | 22.40% | |
| 94 | NVV1Novavax, Inc. | 48,168 | $3.5B | 20.39% | |
| 95 | ALECAlector, Inc. | 239,228 | $3.4B | 19.59% | |
| 96 | ATYRaTyr Pharma, Inc. | 625,000 | $3.3B | 19.21% | |
| 97 | CYTCyteir Therapeutics, Inc. | 812,640 | $3.1B | 17.61% | |
| 98 | DNLIDenali Therapeutics Inc. | 88,738 | $2.9B | 16.40% | |
| 99 | KZRKezar Life Sciences, Inc. | 139,676 | $2.3B | 13.34% | |
| 100 | —TCR2 Therapeutics Inc. | 753,064 | $2.1B | 11.94% |
Page 1 of 2Next